World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
63
Citations
18876
World Ranking
2684
National Ranking
50

Ola Weiland publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Ola Weiland sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 287 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Ola Weiland D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Ola Weiland sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 63 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Ola Weiland is affiliated with Karolinska University Hospital in Sweden and has extensive research experience predominantly in the field of Medicine, with a particular focus on Hepatology and Epidemiology. Their research spans several subfields including Infectious Diseases, Economics and Econometrics, and Pathology and Forensic Medicine.

The scientist has contributed to the study of liver diseases and viral infections, with a strong emphasis on Hepatitis C and Hepatitis B viruses. Their work often intersects with topics related to liver disease diagnosis, treatment, and transplantation, as well as HIV, drug use, sexual risk behaviors, and pharmaceutical economics and policy.

Notable recent publications by Ola Weiland include the following:

  • "Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes" (2020, Hepatology)
  • "Significant decrease in injection risk behaviours among participants in a needle exchange programme" (2020, Infectious Diseases)
  • "Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity" (2020, Antimicrobial Agents and Chemotherapy)
  • "Hepatitis C elimination - Macro-elimination" (2020, Liver International)
  • "Value appropriation in hepatitis C" (2021, The European Journal of Health Economics)

The frequent co-authors working alongside Ola Weiland include:

  • Martin Kåberg
  • Rune Wejstål
  • Soo Aleman
  • Magdalena Ydreborg
  • Peter Lindgren

Among the publication venues where Ola Weiland most frequently appears are:

  • Hepatology
  • Infectious Diseases
  • Scandinavian Journal of Gastroenterology
  • Antimicrobial Agents and Chemotherapy
  • Liver International

Their research covers key topics such as:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • HIV, Drug Use, Sexual Risk
  • Pharmaceutical Economics and Policy
  • HIV/AIDS Research and Interventions

Best Publications

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    Jordan J. Feld;Kris V. Kowdley;Eoin Coakley;Samuel Sigal

  • Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

    Stefan Zeuzem;Geoffrey M. Dusheiko;Riina Salupere;Alessandra Mangia

  • Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

    Olle Reichard;Gunnar Norkrans;Aril Frydén;Jean-Henrik Braconier

  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

    Stefan Zeuzem;Maria Buti;Peter Ferenci;Jan Sperl

  • Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

    Alfredo Alberti;Nathan Clumeck;Simon Collins;Wolfram Gerlich

  • ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

    Pietro Andreone;Massimo G. Colombo;Jeffrey V. Enejosa;Iftihar Koksal

  • Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

    Geoffrey Dusheiko;Janice Main;Howard Thomas;Olle Reichard

  • Ribavirin treatment for chronic hepatitis C.

    O. Reichard;J. Andersson;R. Schvarcz;O. Weiland

  • The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

    Catharina Hultgren;David R. Milich;Ola Weiland;Matti Sällberg

  • Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

    Adriaan J. van der Meer;Jordan J. Feld;Harald Hofer;Piero L. Almasio

  • Epidemiology and the initial presentation of autoimmune hepatitis in Sweden : A nationwide study

    Mårten Werner;Hanne Prytz;Bodil Ohlsson;Sven Almer

  • A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis

    Soo Aleman;Nogol Rahbin;Ola Weiland;Loa Davidsdottir

  • Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study

    Pierre Pradat;Alfredo Alberti;Thierry Poynard;Juan Ignacio Esteban

  • Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

    Graham R. Foster;Christophe Hézode;Jean–Pierre Bronowicki;Giampiero Carosi

  • Limited humoral immunity in hepatitis C virus infection.

    Margaret Chen;Matti Sällberg;Anders Sönnerborg;Ola Weiland

  • Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

    Tania Mara Welzel;Jörg Petersen;Kerstin Herzer;Peter Ferenci

  • High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks

    Olle Reichard;Ulla Foberg;Aril Frydén;Lars Mattsson

  • Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

    Olle Reichard;Hans Glaumann;Aril Frydén;Gunnar Norkrans

  • Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials

    Solko W. Schalm;Ola Weiland;Bettina E. Hansen;Michele Milella

  • Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

    Bart Veldt;G. Saracco;N. Boyer;C. Camma

Frequent Co-Authors

Gunnar Norkrans
Gunnar Norkrans University of Gothenburg
Anders Sönnerborg
Anders Sönnerborg Karolinska Institute
Peter Ferenci
Peter Ferenci Medical University of Vienna
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
David R. Milich
David R. Milich Scripps Health
Graham R. Foster
Graham R. Foster Queen Mary University of London
Christophe Hézode
Christophe Hézode Université Paris Cité
Ulrich Spengler
Ulrich Spengler University of Bonn
George Klein
George Klein Karolinska Institute
Joakim Lundeberg
Joakim Lundeberg Royal Institute of Technology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online degrees can open doors to diverse career opportunities in the healthcare and research fields. Programs such as the online cahiim accredited health information management degree provide valuable skills in managing medical data, an essential aspect of clinical research and laboratory settings.

For those seeking quicker entry into healthcare administration, the best fastest online medical billing and coding certificate programs offer certification pathways that can complement a background in microbiology by enhancing knowledge of healthcare documentation and reimbursement processes.

While traditional medical degrees often require in-person training, several options exist for remote learning. Exploring what medical degree can i get online reveals options that blend clinical knowledge with flexible study formats, ideal for working professionals aiming to expand their qualifications in health sciences.

Additionally, advanced public health education through which online mph programs are easiest to get into can equip microbiology graduates with skills in epidemiology and health policy, further broadening their career pathways in research, public health, and healthcare management.

Best Scientists Citing Ola Weiland

Trending Scientists

Recently Published Articles